Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The former is currently awaiting FDA approval for a handful of oral, daily GLP-1 agonists, while the latter is developing combination therapies that use their muscle-preserving antibodies, trevogrumab and garetosmab, alongside GLP-1 drugs like Wegovy and Ozempic, to improve fat loss while preserving muscle mass
Research suggests the anabolic ceiling for most individuals occurs around 40-50 mcg/day (Philippou et al., 2007)
DECREASED BODY FAT: increases fat metabolism which can lead to overall improvements in body composition
Retatrutide is currently undergoing trials and has yet to achieve approval
In a Phase 1b trial conducted in China, participants receiving the highest dose of UBT251 demonstrated an average weight loss of 15.1% over 12 weeks, while the placebo group gained 1.5%
Jastreboff, A.M., et al
US$ 20.72
US$ 22.09
US$ 24.98
US$ 29.33
US$ 21.35
US$ 23.88
US$ 29.89
